Plain-English translation of NCT06821048 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called PTC13, which uses specially engineered immune cells called CAR-T cells to fight certain advanced cancers. The cells are designed to recognize and attack cancer cells that have a specific marker called CEA. Researchers will give patients different doses of these cells through an infusion into the abdomen to see which dose works best and is safest.
Many patients with advanced cancers like colorectal, stomach, and pancreatic cancer stop responding to standard treatments like chemotherapy. This medication is being developed as a new option for these patients who have run out of effective treatment choices.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo blood tests and imaging to confirm you qualify. Then, doctors will collect immune cells from your blood through a process called apheresis, which takes a few hours. After your cells are engineered in the laboratory, you will receive an infusion of the treated cells directly into your abdomen. You will be monitored closely in the hospital for safety, and then followed with regular clinic visits and scans to see how the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China